Bruce Klein, MD, was recently awarded a Graduate School Fall Competition Award of approximately $35,000 for his project, “Targeting hybrid histidine kinase for broad spectrum antifungal therapy.” With this funding, Dr. Klein and his lab will build on their work with an exciting drug target: group III hybrid histidine kinases (HHKs) and will use an agricultural compound to probe how constitutively activating HHK induces fungal death. They’ll collaborate with the NIH, who has employed their cell based reporter to screen for similar compounds that target HHK and offer new drug leads.